SCHEMBL20227232

SCHEMBL20227232

CC(C)(S)c1cccc(N2CCOCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
KMO O15229 1/20 0.49
AGXT P21549 1/20 0.47
ALDH1A1 P00352 4/20 0.43
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR1D P28221 1/20 0.43
HTR2C P28335 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
MAPT P10636 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTT P42858 2/20 0.42
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
RAB9A P51151 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4402783 0.87 LMNA (0.53) LMNAKMOAGXTALDH1A1HTR3E
SCHEMBL23841128 0.84 AGXT (0.50) LMNAKMOAGXTALDH1A1HTR3E
SCHEMBL13763203 0.81 AGXT (0.48) LMNAKMOAGXTALDH1A1HTR3E
SCHEMBL5739149 0.80 ALDH1A1 (0.66) LMNAKMOALDH1A1HTR3EHTR3B
SCHEMBL27329825 0.78 LMNA (0.71) LMNAKMOAGXTALDH1A1MAPT
SCHEMBL25094093 0.78 PRKDC (0.48) LMNAKMOAGXTALDH1A1MAPT
SCHEMBL14385886 0.77 AGXT (0.44) LMNAKMOAGXTALDH1A1HTR3E
SCHEMBL18675303 0.76 CCR6 (0.46) LMNAALDH1A1MAPTMEN1KMT2A
SCHEMBL296072 0.75 KMO (0.50) LMNAKMOAGXTALDH1A1HTR3E
SCHEMBL487317 0.74 LMNA (0.59) LMNAKMOAGXTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766879-B2 Pyrimidine derivatives as kinase inhibitors and their therapeutical applications NANTBIOSCIENCE, INC. (US) 2020-09-08 US disclosed
US-20180155327-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. 2018-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766879-B2 Pyrimidine derivatives as kinase inhibitors and their therapeutical applications DCK, TK1, DTYMK LMNA 3575/4885KMO 1451/4885AGXT 2337/4885
US-20180155327-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS DCK, TK1, DTYMK LMNA 3575/4885KMO 1451/4885AGXT 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.